Pediatric Thoracic Empyema-Outcomes of Intrapleural Thrombolytics: Ten Years of Experience.
Pediatric Thoracic Empyema-Outcomes of Intrapleural Thrombolytics: Ten Years of Experience.
复制标题
DOI：
10.1177/2333794x20928200
复制
发表时间：
2020-01-01
影响因子：
2.2
通讯作者：
Yaldo, Fitoon
中科院分区：
文献类型：
--
作者：
Baram, Aram;Yaldo, Fitoon
介绍。小儿胸脓胸是一种发病率越来越高的特殊疾病。关于最佳管理策略的共识仍在不断发展。我们描述了我们单中心10年的经验，在简单开胸引流技术失败后，采用组织型纤溶酶原激活剂胸腔内溶栓作为一线治疗。方法。观察性前瞻性研究包括所有因肺旁积液入院并接受胸腔内溶栓治疗的1天至18岁的儿童。结果。2008年1月至2018年12月，对95例不同分期的胸膜内溶栓治疗。所需溶栓剂量为2.1（范围= 1-3），平均引流量为1050 mL（范围= 400-2500 mL）。平均总住院天数为7.3天。完全再扩张是94例（98.9%）患者的主要结局。结论。胸膜内溶栓治疗复杂的小儿胸胸脓肿效果良好，尤其在资源有限的国家应予以鼓励。
Introduction. Pediatric thoracic empyema is a special entity with increasing frequency. Consensus regarding the best management strategy is still evolving. We describe our single-center 10-year experience adopting intrapleural thrombolytics using tissue plasminogen activator as first-line treatment following failure of simple thoracostomy drainage techniques. Methods. Observational prospective study included all children from 1 day to 18 years admitted for parapneumonic effusion and treated with intrapleural thrombolytics. Results. From January 2008 to December 2018, 95 patients were treated by intrapleural thrombolytics for different stages of empyema thoracis. Number of thrombolytic doses required is 2.1 (range = 1-3), and mean amount of drainage is 1050 mL (range = 400-2500 mL). Mean total days of hospitalization is 7.3 days. Complete re-expansion was the primary outcome in 94 patients (98.9%). Conclusion. Intrapleural thrombolytics in complicated pediatric thoracic empyema results in excellent outcome and should be encouraged particularly in limited resource countries.